Literature DB >> 18319308

24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment.

Nea Kalleinen1, Päivi Polo-Kantola, Kerttu Irjala, Tarja Porkka-Heiskanen, Tero Vahlberg, Arho Virkki, Olli Polo.   

Abstract

OBJECTIVE: Our objective was to study the 24-h profiles of GH, prolactin (PRL), and cortisol concentrations in older postmenopausal and middle-aged premenopausal women, before and after estrogen-progestin treatment (EPT).
DESIGN: The study was a randomized, placebo-controlled, double-blind trial. GH, PRL, and cortisol were sampled every 20 min for 24 h in 18 postmenopausal (aged 58-70 yr) and 17 premenopausal (aged 45-51 yr) women before and after 6 months of EPT.
RESULTS: The mean 24-h GH (1.0 vs. 1.8 mU/liter, P = 0.033) and PRL (6.8 vs. 10.0 ng/ml, P = 0.009) concentrations were lower in postmenopausal than in premenopausal women. After EPT, the postmenopausal GH and PRL did not differ from premenopausal baseline levels. Postmenopausal mean 24-h GH (P < 0.001) and PRL (P = 0.002), daytime GH (P < 0.001) and nighttime PRL (P = 0.004) were higher during EPT compared with placebo. Cortisol levels did not differ. Premenopausal mean nighttime PRL (P = 0.026) and cortisol (P = 0.018) were higher during EPT compared with placebo. Postmenopausal PRL and premenopausal GH and PRL concentrations were higher at night than during the day. EPT did not alter this pattern.
CONCLUSIONS: Menopause was associated with decreased 24-h levels of GH and PRL, which were reversible with EPT. In contrast, cortisol levels were not affected by menopause or EPT. In middle-aged premenopausal women, the studied effects of EPT were limited to nighttime increases of PRL and cortisol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319308     DOI: 10.1210/jc.2007-2677

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Plasma prolactin level and risk of incident hypertension in postmenopausal women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

Review 2.  The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Authors:  Alexander T Faje; Anne Klibanski
Journal:  Endocrine       Date:  2014-06-03       Impact factor: 3.633

3.  Estradiol-modified prolactin secretion independently of action potentials and Ca2+ and blockade of outward potassium currents in GH3 cells.

Authors:  Manuel Sánchez; Lorena Suárez; Begoña Cantabrana; Javier Bordallo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-10-17       Impact factor: 3.000

Review 4.  Prolactinomas and menopause: any changes in management?

Authors:  Yona Greenman
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

5.  Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.

Authors:  Zufei Zhang; Muhammad Farooq; Bhagwat Prasad; Sue Grepper; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2015-03-23       Impact factor: 3.922

6.  Cortisol levels during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell; Kathleen Smith-Dijulio
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

7.  Effects of estrogen versus estrogen and progesterone on cortisol and interleukin-6.

Authors:  Kate M Edwards; Paul J Mills
Journal:  Maturitas       Date:  2008-11-17       Impact factor: 4.342

8.  The Effects of Elaeagnus angustifolia L. on the Thyroid-Stimulating Hormone, Dehydroepiandrosterone-Sulfate, Prolactin and Cortisol Levels in Post-Menopausal Women: A Double-Blind, Randomized, and Placebo-Controlled Study.

Authors:  Fatemeh Jalalvand; Arezou Rezaei; Bita Badehnoosh; Mehdi Yaseri; Mostafa Qorbani; Farzaneh Emaminia; Mahzad Shabani
Journal:  Front Pharmacol       Date:  2021-07-07       Impact factor: 5.810

9.  Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women.

Authors:  Therése Andersson; Kotryna Simonyte; Ruth Andrew; Magnus Strand; Jonas Burén; Brian R Walker; Cecilia Mattsson; Tommy Olsson
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

10.  Association between Visceral and Bone Marrow Adipose Tissue and Bone Quality in Sedentary and Physically Active Ovariectomized Wistar Rats.

Authors:  Hélder Fonseca; Andrea Bezerra; Ana Coelho; José Alberto Duarte
Journal:  Life (Basel)       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.